Document is current
Any future updates will be listed below
-
Authors
Jia, Linying
Qu, Pengxiang https://orcid.org/0000-0001-7858-9124
Zhao, Yang https://orcid.org/0000-0002-1428-5145
Bai, Liang
Ren, Honghao
Cheng, Ao
Ma, Zeyao
Ding, Cheng
Deng, Yongjie
Kong, Lingxuan
Zhao, Ying
Rom, Oren
Chen, Yajie
Alam, Naqash
Cao, Wenbin
Zhai, Sixue https://orcid.org/0009-0006-0602-1007
Zheng, Zuowen
Hu, Zhi
Wang, Lu
Chen, Yabing
Zhao, Sihai
Zhang, Jifeng https://orcid.org/0000-0001-5161-4705
Fan, Jianglin
Chen, Y. Eugene https://orcid.org/0000-0003-2357-7825
Liu, Enqi
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81970425)
- License Information
-
More Information
Article History
Received: 4 January 2024
Revised: 18 February 2025
Accepted: 5 March 2025
First Online: 7 April 2025
Competing interests
: Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are inventors of the patent application (Tri-peptides and treatment of metabolic, cardiovascular, and inflammatory disorders: PCT/US2019/046052). Y. Eugene Chen is the founder of Diapin Therapeutics, Inc. and provided DT-109 for the current study. All other authors declare that they have no conflict of interest.
